The mean of analysts' price targets for INmune Bio, Inc. (INMB) points to a 98.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...
INMB earnings call for the period ending June 30, 2022.
Company to Host Conference Call Today, August 3, at 4:30pm ET...
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc....
Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...
In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to...
The consensus price target hints at a 104.7% upside potential for INmune Bio, Inc. (INMB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Malibu (MBUU), Cantaloupe (CTLP), INmune (INMB), Swedish Match (SWMAY) and GATX.
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.